Top Markets
#1 Akedo Akedo +58.47%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.05%
#4 Velvet Velvet +41.93%
#5 Black Phoenix Black Phoenix +34.54%
#6 τemplar τemplar +26.86%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +18.38%
#8 Bitway Bitway +17.87%
#9 Perle Perle +16.15%
#10 Cap Cap +15.03%
Coin of the day
Akedo Akedo
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Altamira Therapeutics Ltd. Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd.

CYTO
Classifica tra le azioni #38206
Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new... Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new treatments for critical medical needs that are currently underserved. Its marketed offerings include Bentrio, a non-pharmaceutical nasal spray designed for individual protection against prevalent airborne viruses and allergens. The company is also heavily invested in developing RNA therapeutics specifically for extrahepatic targets. This includes their preclinical OligoPhore and SemaPhore platforms, engineered for the effective delivery of oligonucleotides and mRNA. In its clinical-stage portfolio, AM-125 is undergoing Phase II trials for the intranasal treatment of vertigo. Additionally, Keyzilen and Sonsuvi are both in Phase III clinical development; Keyzilen is focused on acute inner ear tinnitus, and Sonsuvi addresses acute inner ear hearing loss. Established in 2003 and headquartered in Hamilton, Bermuda, Altamira Therapeutics conducts operations across Switzerland, the United States, Europe, and Australia. The company officially adopted the name Altamira Therapeutics Ltd. in July 2021, prior to which it was known as Auris Medical Holding Ltd.
Prezzo delle azioni
$0.3
Ultima sincronizzazione: 2026-02-10
Capitalizzazione di mercato
$1.13M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
328.57%
Paese
BM
Scambia Altamira Therapeutics Ltd. (CYTO)

Categoria

Healthcare
Utile per Altamira Therapeutics Ltd. (CYTO)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Altamira Therapeutics Ltd., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Altamira Therapeutics Ltd. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE